Second-line chemo with or without bevacizumab for colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 study compares two treatment plans for people with metastatic colorectal cancer that got worse or caused side effects after first chemotherapy. It looks at whether adding bevacizumab (a medicine that targets blood vessels feeding tumors) improves outcomes versus using a different chemotherapy approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed metastatic colorectal adenocarcinoma that cannot be removed by surgery (not appendix or anal canal cancer).
- You’re age 18 or older and can complete study steps on your own (performance status 0–2).
- You stopped first-line chemotherapy for metastatic disease because it didn’t work or caused intolerable side effects (or you relapsed within 180 days after adjuvant chemo).
- You have enough blood counts and organ function on recent lab tests (done within 14 days before enrollment).
- You do not have certain serious health problems like brain metastases, uncontrolled diabetes/heart disease, active infection (including hepatitis), or significant bleeding risks.
- You haven’t previously taken irinotecan, and you’re not taking atazanavir (a specific HIV medicine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
This Phase 3 trial studies whether adding targeted therapy to standard chemotherapy after surgery helps people with stage T3-4, N2 colon cancer live longer or have fewer cancer returns. You would be assigned to receive chemotherapy with targeted therapy or chemotherapy alone, based on the study plan.
This trial studies serplulimab (an immune-related drug) together with bevacizumab and chemotherapy to treat metastatic colorectal (colon) cancer that cannot be removed with surgery. It aims to see whether this combination improves outcomes and is safe.
This trial tests a combination of drugs for people with advanced colorectal cancer that has worsened after first treatment. It aims to see if this new mix can help control the cancer better.
This trial compares two standard chemotherapy combinations for people whose colorectal cancer has spread and cannot be removed with surgery. Depending on certain genetic markers, participants also receive either bevacizumab or cetuximab to help the treatment work better.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
Hear when a new Neoplasm Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.